{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:43:13Z","timestamp":1787949793150,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.neuropharm.2023.109610","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T01:52:15Z","timestamp":1685152335000},"page":"109610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Psychedelics: Threshold of a Therapeutic Revolution"],"prefix":"10.1016","volume":"236","author":[{"given":"D.J.","family":"Heal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Belouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109610_bib1","article-title":"More than meets the eye: the role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics","volume":"223","author":"Aqil","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109214","article-title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","volume":"219","author":"Belouin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib3","article-title":"Considerations in assessing the abuse potential of psychedelics during drug development","volume":"224","author":"Calderon","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib4","article-title":"Canalization and plasticity in psychopathology","volume":"226","author":"Carhart-Harris","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib5","article-title":"Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines","volume":"225","author":"Heal","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109220","article-title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling","volume":"218","author":"Henningfield","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib7","article-title":"The varieties of psychedelic law","volume":"226","author":"Marks","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109232","article-title":"Psychedelics as potent anti-inflammatory therapeutics","volume":"219","author":"Nichols","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib9","article-title":"Psychedelics therapeutics: what we know, what we think, and what we need to research","volume":"223","author":"Nutt","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109127","article-title":"Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations","volume":"214","author":"Ortiz","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109174","article-title":"Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care","volume":"216","author":"Ross","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109166","article-title":"Psychedelics as preventive treatment in headache and chronic pain disorders","volume":"215","author":"Schindler","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109426","article-title":"Psychedelics: science sabotaged by social media","volume":"227","author":"Sellers","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109165","article-title":"Novel ethical and policy issues in psychiatric uses of psychedelic substances","volume":"216","author":"Smith","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib15","article-title":"Mescaline: the forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109504","article-title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders","volume":"231","author":"Wulff","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109610_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109467","article-title":"National Institutes of Health psilocybin research speaker series: state of the science, regulatory and policy landscape, research gaps, and opportunities","volume":"230","author":"Xi","year":"2023","journal-title":"Neuropharmacology"},{"issue":"Apr 2","key":"10.1016\/j.neuropharm.2023.109610_bib18","article-title":"Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs","volume":"2023","author":"Zia","year":"2023","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:25:28Z","timestamp":1758439528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":18,"alternative-id":["S0028390823002009"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109610","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics: Threshold of a Therapeutic Revolution","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109610"}}